Pictet Asset Management (Switzerland)’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$877K	Sell	22,829 -1,151,927	-98%	-$29.6M	﹤0.01%	1015
2023 Q1	$27.2M	Buy	1,174,756 +8,592	+0.7%	+$205K	0.03%	392
2022 Q4	$30.6M	Buy	1,166,164 +484,052	+71%	+$10.7M	0.04%	354
2022 Q3	$13.4M	Buy	+682,112	New	+$13.7M	0.02%	512

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s KDNY Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Chinook Therapeutics, Inc. Common Stock (KDNY) stake by 98% in Q2 2023, selling an estimated $29.6M and leaving 22,829 shares worth $877K. The position accounts for ﹤0.01% of the portfolio, ranked #1015.

Pictet Asset Management (Switzerland) first reported a position in KDNY in Q3 2022 and has held it in 4 quarters since. The position peaked at $30.6M in Q4 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

Pictet Asset Management (Switzerland) held 22,829 shares of Chinook Therapeutics, Inc. Common Stock worth $877K as of Q2 2023.
Pictet Asset Management (Switzerland) sold 1,151,927 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $29.6M.
Chinook Therapeutics, Inc. Common Stock made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1015 holding.
Pictet Asset Management (Switzerland) first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2022 and has held it in 4 quarters since.
Pictet Asset Management (Switzerland)'s Chinook Therapeutics, Inc. Common Stock position peaked at $30.6M in Q4 2022.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.